Document and Entity Information (USD $)	12 Months Ended
Document and Entity Information (USD $)	Dec. 31, 2014	Mar. 10, 2015	Jun. 30, 2014
Document And Entity Information [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2014
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	FY
Trading Symbol	CPRX
Entity Registrant Name	CATALYST PHARMACEUTICAL PARTNERS, INC.
Entity Central Index Key	0001369568
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		81,444,849
Entity Public Float			$ 155,035,298

Balance Sheets (USD $)	Dec. 31, 2014	Dec. 31, 2013
Current Assets:
Cash and cash equivalents	$ 9,096,778	$ 2,215,958
Certificates of deposit	3,715,383	4,011,576
Short-term investments	26,462,962	17,483,062
Prepaid expenses and other current assets	4,552,698	1,609,442
Total current assets	43,827,821	25,320,038
Property and equipment, net	71,377	40,628
Deposits	8,888	8,888
Total assets	43,908,086	25,369,554
Current Liabilities:
Accounts payable	1,814,210	850,789
Accrued expenses and other liabilities	4,040,816	1,288,820
Total current liabilities	5,855,026	2,139,609
Accrued expenses and other liabilities, non-current	15,839	19,131
Warrants liability, at fair value	2,794,891	1,819,562
Total liabilities	8,665,756	3,978,302
Commitments and contingencies
Stockholders' equity:
Preferred stock, $0.001 par value, 5,000,000 shares authorized: none issued and outstanding at December 31, 2014 and 2013
Common stock, $0.001 par value, 100,000,000 shares authorized; 69,119,092 shares and 54,132,937 shares issued and outstanding at December 31, 2014 and 2013, respectively	69,119	54,133
Additional paid-in capital	105,015,871	75,670,718
Accumulated deficit	(69,842,660)	(54,333,599)
Total stockholders' equity	35,242,330	21,391,252
Total liabilities and stockholders' equity	$ 43,908,086	$ 25,369,554

Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	69,119,092	54,132,937
Common stock, shares outstanding	69,119,092	54,132,937

Statements of Operations (USD $)	12 Months Ended
Statements of Operations (USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income Statement [Abstract]
Revenues	$ 0	$ 0	$ 0
Operating costs and expenses:
Research and development	10,117,774	8,096,774	2,659,597
General and administrative	4,473,654	2,214,884	2,561,543
Total operating costs and expenses	14,591,428	10,311,658	5,221,140
Loss from operations	(14,591,428)	(10,311,658)	(5,221,140)
Other income, net	76,233	47,421	14,976
Change in fair value of warrants liability	(993,866)	(1,890,359)	1,129,778
Loss before income taxes	(15,509,061)	(12,154,596)	(4,076,386)
Provision for income taxes	0	0	0
Net loss	$ (15,509,061)	$ (12,154,596)	$ (4,076,386)
Net loss per share - basic and diluted	$ (0.24)	$ (0.27)	$ (0.14)
Weighted average shares outstanding - basic and diluted	64,142,534	45,452,447	30,033,108

Statement of Stockholders' Equity (USD $)	Total	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]
Beginning Balance at Dec. 31, 2011	$ 3,760,698	$ 24,701	$ 41,838,614	$ (38,102,617)
Issuance of common stock, net	33,124	53	33,071
Issuance of stock options for services	340,039		340,039
Issuance of common stock and warrants, net	9,564,640	10,000	9,554,640
Issuance of common stock upon note conversion	5,000,000	6,667	4,993,333
Net loss	(4,076,386)			(4,076,386)
Ending Balance at Dec. 31, 2012	14,622,115	41,421	56,759,697	(42,179,003)
Issuance of common stock, net	14,095,194	8,850	14,086,344
Issuance of stock options for services	175,855		175,855
Exercise of warrants for common stock	4,652,684	3,862	4,648,822
Net loss	(12,154,596)			(12,154,596)
Ending Balance at Dec. 31, 2013	21,391,252	54,133	75,670,718	(54,333,599)
Issuance of common stock, net	26,725,130	13,024	26,712,106
Issuance of stock options for services	767,838		767,838
Amortization of restricted stock for services	10,131		10,131
Exercise of warrants for common stock	1,335,040	1,262	1,333,778
Exercise of stock options, for common stock	522,000	700	521,300
Net loss	(15,509,061)			(15,509,061)
Ending Balance at Dec. 31, 2014	$ 35,242,330	$ 69,119	$ 105,015,871	$ (69,842,660)

- Definition

This element represents the amount of recognized equity-based compensation during the period, that is, the amount recognized as expense in the income statement (or as asset if compensation is capitalized). Alternate captions include the words "stock-based compensation".

+ References+ Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References+ Details

- Definition

Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.

+ References+ Details

Statements of Cash Flows (USD $)	12 Months Ended
Statements of Cash Flows (USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Operating Activities:
Net loss	$ (15,509,061)	$ (12,154,596)	$ (4,076,386)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	26,574	22,483	10,889
Stock-based compensation	777,969	175,855	340,039
Change in fair value of warrants liability	993,866	1,890,359	(1,129,778)
(Increase) decrease in:
Prepaid expenses and other current assets and deposits	(2,943,256)	(299,972)	(1,110,354)
Increase (decrease) in:
Accounts payable	963,421	(514,874)	1,101,729
Accrued expenses and other liabilities	2,748,704	1,005,071	(276,505)
Net cash used in operating activities	(12,941,783)	(9,875,674)	(5,140,366)
Investing Activities:
Capital expenditures	(57,323)	(9,432)	(52,382)
Purchase of short-term investments	(8,979,900)	(9,978,618)	(7,504,444)
Proceeds (purchase) of certificates of deposit	296,193	2,491,249	(6,502,825)
Net cash used in investing activities	(8,741,030)	(7,496,801)	(14,059,651)
Financing Activities:
Proceeds from issuance of common stock and warrants, net	26,725,130	14,071,694	9,564,640
Proceeds from issuance of convertible promissory note			5,000,000
Proceeds from exercise of warrants	1,316,503	4,083,300	16,249
Proceeds from exercise of options	522,000	23,500
Net cash provided by financing activities	28,563,633	18,178,494	14,580,889
Net increase (decrease) in cash and cash equivalents	6,880,820	806,019	(4,619,128)
Cash and cash equivalents - beginning of period	2,215,958	1,409,939	6,029,067
Cash and cash equivalents - end of period	9,096,778	2,215,958	1,409,939
Non-cash investing and financing activities:
Exercise of liability classified warrants for common stock	18,537	569,384	16,875
Conversion of note to common stock			$ 5,000,000

Organization and Description of Business

12 Months Ended

Dec. 31, 2014

Accounting Policies [Abstract]

Organization and Description of Business

1.	Organization and Description of Business

Catalyst Pharmaceutical Partners, Inc. (the “Company”) is a development-stage biopharmaceutical company focused on the development and commercialization of prescription drugs targeting rare (orphan) neurological diseases and disorders, including Lambert-Eaton Myasthenic Syndrome (LEMS) and infantile spasms. The Company was incorporated in Delaware in July 2006. It is the successor by merger to Catalyst Pharmaceutical Partners, Inc., a Florida corporation, which commenced operations in January 2002.

Since inception, the Company has devoted substantially all of its efforts to business planning, research and development, recruiting management and technical staff, acquiring operating assets and raising capital. The Company’s primary focus is on the development and commercialization of its drug candidates. The Company has incurred operating losses in each period from inception through December 31, 2014. The Company has been able to fund its cash needs to date through several public and private offerings of its common stock and warrants, through government grants, and through an investment by a strategic purchaser. See Note 11.

Capital Resources

On January 31, 2014, the Company filed a Shelf Registration Statement on Form S-3 (the 2014 Shelf Registration Statement) with the U.S. Securities and Exchange Commission (SEC) to sell up to $100 million of common stock. This registration statement (file No. 333-193699) was declared effective by the SEC on March 19, 2014. On April 3, 2014, the Company sold 13,023,750 shares of its common stock in an underwritten public offering under the 2014 Shelf Registration Statement, raising net proceeds of approximately $26.7 million. Subsequent to year end, on February 4, 2015, the Company sold 11,500,000 shares of its common stock in an underwritten public offering under the 2014 Shelf Registration Statement, raising net proceeds of approximately $34.7 million. (See Note 11). While there can be no assurance, based on currently available information, the Company estimates that it currently has sufficient working capital to support its operations through the end of 2016. The Company will require additional capital to support its operations in periods after 2016.

The Company may raise required funds in the future through public or private equity offerings, debt financings, corporate collaborations, governmental research grants or other means. The Company may also seek to raise new capital to fund additional product development efforts, even if it has sufficient funds for its planned operations. Any sale by the Company of additional equity or convertible debt securities could result in dilution to the Company’s current stockholders. There can be no assurance that any such required additional funding will be available to the Company at all or available on terms acceptable to the Company. Further, to the extent that the Company raises additional funds through collaborative arrangements, it may be necessary to relinquish some rights to the Company’s drug candidates or grant sublicenses on terms that are not favorable to the Company. If the Company is not able to secure additional funding when needed, the Company may have to delay, reduce the scope of, or eliminate one or more research and development programs, which could have an adverse effect on the Company’s business.

Basis of Presentation and Significant Accounting Policies

12 Months Ended

Dec. 31, 2014

Accounting Policies [Abstract]

Basis of Presentation and Significant Accounting Policies

2.	Basis of Presentation and Significant Accounting Policies

USE OF ESTIMATES. The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.

CASH AND CASH EQUIVALENTS. The Company considers all highly liquid instruments, purchased with an original maturity of three months or less to be cash equivalents. Cash equivalents consist mainly of money market funds. The Company has substantially all of its cash and cash equivalents deposited with one financial institution.

CERTIFICATES OF DEPOSIT. The certificates of deposit were issued by a banking institution and are recorded at cost plus accrued interest. The original maturity was greater than three months but did not exceed one year. Interest income is recorded in the statement of operations as it is earned. Carrying value at December 31, 2014 and 2013 approximates fair value.

SHORT-TERM INVESTMENTS. The Company invests in short-term investments in high credit-quality funds in order to obtain higher yields on its cash available for investments. As of December 31, 2014 and 2013 short-term investments consisted of a short-term bond fund. Such investments are not insured by the Federal Deposit Insurance Corporation. Short-term investments at December 31, 2014 and 2013 were considered trading securities. Trading securities are recorded at fair value based on the closing market price of the security. For trading securities, the Company recognizes realized gains and losses and unrealized gains and losses to earnings. Unrealized and realized losses on trading securities for the years ended December 31, 2014 and 2013 were nominal and are included in other income, net in the accompanying statements of operations.

PREPAID EXPENSES AND OTHER CURRENT ASSETS. Prepaid expenses and other current assets consist primarily of insurance recoverable, prepaid research fees, prepaid insurance and prepaid subscription fees. Insurance recoverable relates to the securities class action lawsuit proposed settlement to be paid by the Company’s insurance carrier. Prepaid research fees consist of advances for the Company’s product development activities, including drug manufacturing, contracts for pre-clinical studies, clinical trials and studies, regulatory affairs and consulting. Such advances are recorded as expense as the related goods are received or the related services are performed.

PROPERTY AND EQUIPMENT. Property and equipment are recorded at cost. Depreciation is calculated to amortize the depreciable assets over their useful lives using the straight-line method and commences when the asset is placed in service. Useful lives generally range from three years for computer equipment to three to six years for furniture and equipment. Expenditures for repairs and maintenance are charged to expenses as incurred.

OPERATING LEASES. The Company recognizes lease expense on a straight-line basis over the initial lease term. For leases that contain rent holidays, escalation clauses or tenant improvement allowances, the Company recognizes rent expense on a straight-line basis and records the difference between the rent expense and rental amount payable as deferred rent. As of December 31, 2014 and 2013, the Company had $19,997 and $21,877, respectively, of deferred rent in accrued expenses and other liabilities.

FAIR VALUE OF FINANCIAL INSTRUMENTS. The Company’s financial instruments consist of cash and cash equivalents, certificates of deposit, short-term investments, accounts payable and accrued expenses and other liabilities, and warrants liability. At December 31, 2014 and 2013, the fair value of these instruments approximated their carrying value.

FAIR VALUE MEASUREMENTS. Current Financial Accounting Standards Board (FASB) fair value guidance emphasizes that fair value is a market-based measurement, not an entity-specific measurement. Therefore, a fair value measurement should be determined based on the assumptions that market participants would use in pricing the asset or liability. As a basis for considering market participant assumptions in fair value measurements, current FASB guidance establishes a fair value hierarchy that distinguishes between market participant assumptions based on market data obtained from sources independent of the reporting entity (observable inputs that are classified within Levels 1 and 2 of the hierarchy) and the reporting entity’s own assumptions that it believes market participants would use in pricing assets or liabilities (unobservable inputs classified within Level 3 of the hierarchy). Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date. Level 2 inputs are inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. Level 2 inputs may include quoted prices for similar assets and liabilities in active markets, as well as inputs that are observable for the asset or liability (other than quoted prices), such as interest rates, foreign exchange rates, and yield curves that are observable at commonly quoted intervals. Level 3 inputs are unobservable inputs for the asset or liability, which are typically based on an entity’s own assumptions, as there is little, if any, related market activity. In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment, and considers factors specific to the asset or liability.


			Fair Value Measurements at Reporting Date Using
	Balances as of December 31, 2014		Quoted Prices in Active Markets for Identical Assets/Liabilities (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Money market funds	$	7,053,310	$	7,053,310	$	—	$	—

Certificates of deposit	$	3,715,383	$	—	$	3,715,383	$	—

Short-term investments	$	26,462,962	$	26,462,962	$	—	$	—

Warrants liability	$	2,794,891	$	—	$	—	$	2,794,891


			Fair Value Measurements at Reporting Date Using
	Balances as of December 31, 2013		Quoted Prices in Active Markets for Identical Assets/Liabilities (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Money market funds	$	25,693	$	25,693	$	—	$	—

Certificates of deposit	$	4,011,576	$	—	$	4,011,576	$	—

Short-term investments	$	17,483,062	$	17,483,062	$	—	$	—

Warrants liability	$	1,819,562	$	—	$	—	$	1,819,562

WARRANTS LIABILITY. In October 2011, the Company issued 1,523,370 warrants (the 2011 warrants) to purchase shares of the Company’s common stock in connection with a registered direct offering under the 2010 Shelf Registration Statement. The Company accounted for these warrants as a liability measured at fair value due to a provision included in the warrants agreement that provides the warrants holders with an option to require the Company (or its successor) to purchase their warrants for cash in an amount equal to their Black-Scholes Option Pricing Model (the Black-Scholes Model) value, in the event that certain fundamental transactions, as defined, occur. The fair value of the warrants liability is estimated using the Black-Scholes Model which requires inputs such as the expected term of the warrants, share price volatility and risk-free interest rate. These assumptions are reviewed on a quarterly basis and changes in the estimated fair value of the outstanding warrants are recognized each reporting period in the “Change in fair value of warrants liability” line in the statements of operations. As of December 31, 2014 and 2013, 1,242,174 and 1,254,870, respectively, of the 2011 warrants remained outstanding.

RESEARCH AND DEVELOPMENT. Costs incurred in connection with research and development activities are expensed as incurred. These costs consist of direct and indirect costs associated with specific projects as well as fees paid to various entities that perform research related services for the Company.

STOCK-BASED COMPENSATION. The Company recognizes expense in the statement of operations for the fair value of all stock-based payments to employees, directors, scientific advisors and consultants, including grants of stock options and other share-based awards. For stock options, the Company uses the Black-Scholes option valuation model, the single-option award approach and the straight-line attribution method. Using this approach, compensation cost is amortized on a straight-line basis over the vesting period of each respective stock option, generally three to seven years. The Company estimates forfeitures and adjusts this estimate periodically based on actual forfeitures.

For the years ended December 31, 2014, 2013 and 2012, the Company recorded stock-based compensation expense as follows:


	2014		2013		2012
Research and development	$	133,862	$	84,728	$	100,221
General and administrative		644,107		91,127		239,818

Total stock-based compensation	$	777,969	$	175,855	$	340,039

CONCENTRATION OF CREDIT RISK. The financial instruments that potentially subject the Company to concentration of credit risk are cash equivalents (i.e. money market funds), short-term investments and certificates of deposit. The Company places its cash equivalents with high-credit quality financial institutions. These amounts at times may exceed federally insured limits. The Company has not experienced any credit losses in these accounts.

INCOME TAXES. The Company utilizes the asset and liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between financial reporting and tax bases of assets and liabilities and are measured using enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized.

The Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the financial statements is the largest benefit that has a greater than 50 percent likelihood of being realized upon ultimate settlement with the relevant tax authority.

The Company is subject to income taxes in the U.S. federal jurisdiction and various state jurisdictions. Tax regulations within each jurisdiction are subject to the interpretation of the related tax laws and regulations and require significant judgment to apply. The Company is not subject to U.S. federal, state and local tax examinations by tax authorities for years before 2010. If the Company were to subsequently record an unrecognized tax benefit, associated penalties and tax related interest expense would be reported as a component of income tax expense.

COMPREHENSIVE INCOME (LOSS). U.S. generally accepted accounting principles require that all components of comprehensive income (loss) be reported in the financial statements in the period in which they are recognized. Comprehensive income (loss) is net income (loss), plus certain other items that are recorded directly into stockholders’ equity. For all periods presented, the Company’s net loss equals comprehensive loss, since the Company has no items which are considered other comprehensive income (loss).

NET INCOME (LOSS) PER SHARE. Basic income (loss) per share is computed by dividing net income (loss) for the period by the weighted average number of common shares outstanding during the period. Diluted income (loss) per share is computed by dividing net income (loss) for the period by the weighted average number of common shares outstanding during the period, plus the dilutive effect of common stock equivalents, such as convertible preferred stock, stock options and restricted stock units. For all periods presented, all common stock equivalents were excluded because their inclusion would have been anti-dilutive. The potential shares, which are excluded from the determination of basic and diluted net loss per share as their effect is anti-dilutive, are as follows, for the years ended December 31, 2014, 2013 and 2012:


	2014		2013		2012
Options to purchase common stock		3,884,610		3,428,906		3,650,535
Warrants to purchase common stock		3,585,924		4,848,620		8,710,870
Unvested restricted stock		80,000		—		—

Potential equivalent common stock excluded		7,550,534		8,277,526		12,361,405

Potentially dilutive options to purchase common stock as of December 31, 2014 have exercise prices ranging from $0.47 to $3.12. Potentially dilutive options to purchase common stock as of December 31, 2013 and 2012 have exercise prices ranging from $0.47 to $6.00. Potentially dilutive warrants to purchase common stock as of December 31, 2014, 2013 and 2012 have exercise prices ranging from $1.04 to $2.08.

SEGMENT INFORMATION. Management has determined that the Company operates in one reportable segment, which is the development and commercialization of pharmaceutical products.

RECLASSIFICATIONS. Certain prior year amounts in the financial statements have been reclassified to conform to the current year presentation.

RECENTLY ISSUED ACCOUNTING STANDARDS. In June 2014, the FASB issued ASU No. 2014-10, Development Stage Entities (Topic 915): Elimination of Certain Financial Reporting Requirements, Including an Amendment to Variable Interest Entities Guidance in Topic 810, Consolidation. The amendments in this ASU include: i) eliminating the requirement to present inception-to-date information on the statements of income, cash flows, and shareholders’ equity, ii) eliminating the need to label the financial statements as those of a development stage entity, iii) eliminating the need to disclose a description of the development stage activities in which the entity is engaged, and iv) eliminating the requirement to disclose in the first year in which the entity is no longer a development stage entity that in prior years it had been in the development stage. The amendments in ASU No. 2014-10 are effective for public companies for annual and interim reporting periods beginning after December 15, 2014. Early adoption is permitted. The Company has early adopted ASU No. 2014-10, beginning with the interim period ended June 30, 2014.

In August 2014, the FASB issued ASU No. 2014-15, Presentation of Financial Statements—Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. The amendments in this ASU, require management to assess a company’s ability to continue as a going concern and to provide related disclosures in certain circumstances. The guidance will be effective for the annual period ending after December 15, 2016 and subsequent interim and annual periods thereafter. The Company is currently evaluating the impact of this accounting standard update on its financial statements.

Warrants Liability, at Fair Value

12 Months Ended

Dec. 31, 2014

Text Block [Abstract]

Warrants Liability, at Fair Value

3.	Warrants Liability, at Fair Value

The Company allocated approximately $1.3 million of proceeds from its October 2011 registered direct offering to the fair value of common stock purchase warrants issued in connection with the offering that are classified as a liability (the 2011 warrants). The 2011 warrants are classified as a liability because of provisions in such warrants that allow for the net cash settlement of such warrants in the event of certain fundamental transactions (as defined in the warrant agreement). The valuation of the 2011 warrants is determined using the Black-Scholes Model. This model uses inputs such as the underlying price of the shares issued when the warrant is exercised, volatility, risk free interest rate and expected life of the instrument. The Company has determined that the 2011 warrants liability should be classified within Level 3 of the fair value hierarchy by evaluating each input for the Black-Scholes Model against the fair value hierarchy criteria and using the lowest level of input as the basis for the fair value classification. There are six inputs: closing price of the Company’s common stock on the day of evaluation; the exercise price of the warrants; the remaining term of the warrants; the volatility of the Company’s common stock; annual rate of dividends; and the risk free rate of return. Of those inputs, the exercise price of the warrants and the remaining term are readily observable in the warrants agreement. The annual rate of dividends is based on the Company’s historical practice of not granting dividends. The closing price of the Company’s common stock would fall under Level 1 of the fair value hierarchy as it is a quoted price in an active market. The risk free rate of return is a Level 2 input, while the historical volatility is a Level 3 input in accordance with the fair value accounting guidance. Since the lowest level input is a Level 3, the Company determined the 2011 warrants liability is most appropriately classified within Level 3 of the fair value hierarchy. This liability is subject to fair value mark-to-market adjustment each reporting period. The calculated value of the 2011 warrants liability was determined using the Black-Scholes option-pricing model with the following assumptions:


	December 31, 2014			December 31, 2013
Risk free interest rate		0.81	%		0.94	%
Expected term		2.34 years			3.34 years
Expected volatility		112	%		108	%
Expected dividend yield		0	%		0	%
Expected forfeiture rate		0	%		0	%

The following table rolls forward the fair value of the Company’s warrants liability activity for the years ended December 31, 2014, 2013 and 2012:


	2014			2013			2012
Fair value, beginning of period	$	1,819,562		$	498,587		$	1,645,240
Issuance of warrants		—			—			—
Exercise of warrants		(18,537	)		(569,384	)		(16,875	)
Change in fair value		993,866			1,890,359			(1,129,778	)

Fair value, end of period	$	2,794,891		$	1,819,562		$	498,587

During 2014, 12,696 of the 2011 warrants were exercised, with proceeds to the Company of $16,504. During 2013, 256,000 of the 2011 warrants were exercised, with proceeds to the Company of $332,800. During 2012, 12,500 of the 2011 warrants were exercised with proceeds to the Company of $16,249. The Company recognizes the change in the fair value of the warrants liability as a non-operating income or loss in the accompanying statements of operations.

Prepaid Expenses and Other Current Assets

12 Months Ended

Dec. 31, 2014

Text Block [Abstract]

Prepaid Expenses and Other Current Assets

4.	Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consist of the following as of December 31:


	2014		2013
Insurance recoverable (see Note 7)	$	3,500,000	$	—
Prepaid research fees		571,428		1,334,149
Prepaid insurance		385,496		219,651
Prepaid subscriptions fees		30,495		24,643
Prepaid offering costs		20,029		—
Prepaid rent		10,870		7,848
Other		34,380		23,151

Total prepaid expenses	$	4,552,698	$	1,609,442

Property and Equipment

12 Months Ended

Dec. 31, 2014

Property, Plant and Equipment [Abstract]

Property and Equipment

5.	Property and Equipment

Property and equipment, net consists of the following as of December 31:


	2014			2013
Computer equipment	$	95,754		$	81,551
Furniture and equipment		88,816			51,523

		184,570			133,074
Less: Accumulated depreciation		(113,193	)		(92,446	)

Total property and equipment, net	$	71,377		$	40,628

Depreciation expense was $26,574, $22,483 and $10,889, respectively, for the years ended December 31, 2014, 2013 and 2012.

- Definition

The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.

+ References+ Details

Accrued Expenses and Other Liabilities

12 Months Ended

Dec. 31, 2014

Payables and Accruals [Abstract]

Accrued Expenses and Other Liabilities

6.	Accrued Expenses and Other Liabilities

Accrued expenses and other liabilities consist of the following as of December 31:


	2014		2013
Accrued settlement liability (see Note 7)	$	3,500,000	$	—
Accrued pre-clinical and clinical trial expenses		333,928		1,083,749
Accrued professional fees		43,973		117,240
Accrued compensation and benefits		31,956		14,539
Accrued license fees		115,000		65,000
Deferred rent		4,158		2,746
Other		11,801		5,546

Current accrued expenses and other liabilities		4,040,816		1,288,820
Deferred rent—non-current		15,839		19,131

Non-current accrued expenses and other liabilities		15,839		19,131

Total accrued expenses and other liabilities	$	4,056,655	$	1,307,951

The accrued settlement liability of $3,500,000 as of December 31, 2014 is related to the securities class action lawsuit proposed settlement, as disclosed with more particularity in Note 7. The proposed settlement amount is expected to be paid for and covered by the Company’s insurance carrier; therefore, there is a corresponding insurance recoverable recorded in “Prepaid Expenses and Other Current Assets” in the accompanying balance sheet as of December 31, 2014.

Commitments and Contingencies

12 Months Ended

Dec. 31, 2014

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

7.	Commitments and Contingencies

The Company has contracted with drug manufacturers and other vendors, including clinical research organizations (CRO) overseeing the clinical trials of the Company’s drug candidates, to assist in the execution of the Company’s pre-clinical and clinical trials, analysis, and the preparation of material necessary for the future submission of new drug applications (NDA’s) with the U.S. Food and Drug Administration (FDA). The contracts are cancelable at any time, but obligate the Company to reimburse the providers for any time or costs incurred through the date of termination.

The Company has executed a noncancellable operating lease agreement for its corporate office. The lease has free and escalating rent payment provisions. The Company recognizes rent expense under such lease on a straight-line basis over the term of the lease. As of December 31, 2014, future minimum lease payments under the operating lease agreement are as follows:


2015	$	103,902
2016		107,010
2017		100,076

	$	310,988

During June 2011, in connection with the renewal of the corporate office lease, the Company entered into the first amendment to the lease. The amendment extends the original lease term for five years and relocated the Company into another space within the same building. During February 2014, the Company entered into the second amendment of the lease for an additional contiguous space under substantially the same terms. The corporate office lease is cancellable upon the payment of an early termination penalty during 2015. The lease provides for fixed increases in minimum annual rent payments, as well as rent free periods. The total amount of rental payments due over the lease term is being charged to rent expense on the straight-line method over the term of the lease. The differences between rent expense recorded and the amount paid is credited or charged to accrued expenses and other liabilities in the accompanying balance sheets. Rent expense was $90,163, $69,930 and $65,310, respectively, for the years ended December 31, 2014, 2013 and 2012. The Company’s office lease expires in November 2017.

Securities Class Action Lawsuit

In October 2013 and November 2013, three securities class action lawsuits were filed against the Company and certain of its executive officers and directors seeking unspecified damages in the U.S. District Court for the Southern District of Florida (the Court). These complaints, which were substantially identical, purported to state a claim for violation of federal securities laws on behalf of a class of those who purchased the Company’s common stock between October 31, 2012 and October 18, 2013. Two of the cases were voluntarily dismissed by the plaintiffs and the Court granted the Company’s motion to dismiss on the third case on January 3, 2014. However, the Court granted leave to the plaintiffs to file an amended complaint within 20 days.

On January 23, 2014, the plaintiffs filed an amended complaint against the Company and one of its executive officers seeking unspecified damages. The amended complaint purports to state a claim for alleged misrepresentations regarding the development of Firdapse™ on behalf of a class of those who purchased shares of the Company’s common stock between August 27, 2013 and October 18, 2013. In February 2014, the Company filed a motion to dismiss the amended complaint, which was granted in part and denied in part by the Court. Subsequently, on September 29, 2014, the Court certified a class consisting of all persons or entities that purchased shares of the Company’s common stock during the period from August 27, 2013, through October 18, 2013 (the Class Period), and who did not sell such securities prior to October 18, 2013 (excluding: defendants; any entities affiliated with the Company, the present and former officers and directors of the Company or any subsidiary or affiliate thereof; members of such excluded persons’ immediate families and their legal representatives, heirs, successors or assigns; and any entity in which any excluded person has or had a controlling interest).

Following a mediation in mid-October conducted by an independent mediator, the Company entered into a memorandum of understanding (MOU) with the lead plaintiffs in the class action lawsuit to settle the lawsuit. The settlement was then reduced to a formal stipulation of settlement between the parties to the lawsuit, which was filed with the Court on November 21, 2014. The settlement was preliminarily approved by the Court in December 3, 2014, and a final hearing to determine the fairness of the settlement has been scheduled for March 16, 2015.

In connection with the settlement, the Company will pay $3.5 million in return for a dismissal and release of all claims against the defendants. The settlement amount has been placed in escrow by the Company’s insurance carrier, subject to final Court approval of the settlement. Under the proposed settlement, the defendants, and various of their related persons and entities, will receive a full release of all claims that were or could have been brought in the action, as well as all claims that arise out of, are based upon, or relate to the allegations, transactions, facts, representations, omissions or other matters involved in the action related in any way to the purchase or acquisition of the Company’s securities by class members during the class period.

The proposed settlement contains no admission of any liability or wrongdoing on the part of the defendants, each of whom continues to deny all of the allegations against each of them and believes that the claims are without merit. Because the full amount of the proposed settlement payment is expected to be paid by the Company’s insurance carrier, the settlement is not expected to have a material adverse effect on the Company’s financial position or results of operations. There can be no assurance that the settlement will be approved by the Court.

Obligations under capital leases are not significant.

For commitments related to the Company’s license agreements with BioMarin (defined below) and Northwestern (defined below), see Note 8.

- Definition

The entire disclosure for commitments and contingencies.

+ References+ Details

Agreements

12 Months Ended

Dec. 31, 2014

Text Block [Abstract]

Agreements

8.	Agreements

LICENSE AGREEMENT WITH BROOKHAVEN. The Company had a license agreement with Brookhaven Science Associates, LLC, as operator of Brookhaven National Laboratory under contract with the United States Department of Energy (“Brookhaven”), whereby the Company had obtained an exclusive license for several patents and patent applications in the U.S. and outside the U.S. relating to the use of vigabatrin as a treatment for cocaine and other addictions and obsessive-compulsive disorders. This license agreement ran concurrently with the term of the last to expire of the licensed patents, the last of which currently expires in 2023. The Company paid a fee to obtain the license in the amount of $50,000. Under the license agreement, the Company agreed to pay Brookhaven certain milestones and to reimburse them for certain patent related expenses.

On November 8, 2013, effective October 1, 2013, the Company and Brookhaven entered into a termination agreement cancelling the license agreement. As part of that agreement, the Company and Brookhaven entered into mutual releases, including a release from any further obligation for the Company to reimburse Brookhaven for any of Brookhaven’s patent related expenses.

LICENSE AGREEMENT WITH NORTHWESTERN UNIVERSITY. On August 27, 2009, the Company entered into a license agreement with Northwestern University (Northwestern), under which it acquired worldwide rights to commercialize new GABA aminotransferase inhibitors and derivatives of vigabatrin that have been discovered by Northwestern. Under the terms of the license agreement, Northwestern granted the Company an exclusive worldwide license to certain composition of matter patents related to the new class of inhibitors and a patent application relating to derivatives of vigabatrin. The Company has identified and designated the lead compound under this license as CPP-115.

Under the license agreement with Northwestern, the Company is responsible for continued research and development of any resulting product candidates. As of December 31, 2014, the Company had paid Northwestern $251,590 in connection with the license and had accrued license fees of $115,000 and $65,000 as of December 31, 2014 and 2013, respectively, in the accompanying balance sheets for expenses, maintenance fees and milestones. In addition, the Company is obligated to pay certain milestone payments in future years relating to clinical development activities with respect to CPP-115, and royalties on any products resulting from the license agreement. The next milestone payment of $150,000 is due on the earlier of successful completion of the first Phase 2 clinical trial for CPP-115 or August 27, 2015.

LICENSE AGREEMENT WITH NEW YORK UNIVERSITY AND THE FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH. On December 13, 2011, the Company entered into a license agreement with New York University (NYU) and the Feinstein Institute for Medical Research (FIMR) under which it acquired worldwide rights to commercialize GABA aminotransferase inhibitors in the treatment for Tourette Syndrome. The Company is obligated to pay certain milestone payments in future years relating to clinical development activities and royalties on any products resulting from the license agreement.

LICENSE AGREEMENT WITH BIOMARIN. On October 26, 2012, the Company entered into a strategic collaboration with BioMarin Pharmaceutical, Inc. (BioMarin) for Firdapse™. The key components of the collaboration include: (i) the Company licensed the exclusive North American rights to Firdapse™ pursuant to a License Agreement, dated as of October 26, 2012 (the License Agreement) between the Company and BioMarin, and (ii) BioMarin made a $5,000,000 investment in the Company pursuant to the terms of a Convertible Promissory Note and Note Purchase Agreement, dated as of October 26, 2012 (the Investment Agreement). The Investment Agreement provides that the Company will use the $5 million solely for the purpose of developing Firdapse™.

As part of the License Agreement, the Company took over a Phase 3 Trial previously being conducted by BioMarin and is obligated to use its diligent efforts to seek to obtain regulatory approval for and to commercialize Firdapse™ in the United States. The Company was obligated to use diligent efforts to complete the double-blind treatment phase of the Phase 3 Trial within 24 months of entering into the License Agreement, and BioMarin had the right to terminate the License Agreement if such treatment phase had not been completed in such 24-month period (unless the Company was using diligent effort to pursue the completion of such treatment phase and had spent at least $5 million in connection with the conduct of the Phase 3 Trial during such 24 month period, which condition has been satisfied during the third quarter of 2014. ). On September 29, 2014, the Company announced positive top-line results from its Phase 3 Trial of Firdapse™ for the symptomatic treatment of LEMS. Both co-primary endpoints, quantitative myasthenia gravis score (QMG) and subject global impression (SGI) demonstrated statistical significance, as did a secondary endpoint for the physician’s clinical global impression of improvement (CGI-I).

As part of the License Agreement, the Company agreed: (i) to pay BioMarin royalties for seven years from the first commercial sale of Firdapse™ equal to 7% of net sales (as defined in our license agreement) in North America for any calendar year for sales up to $100 million, and 10% of net sales in North America in any calendar year in excess of $100 million; (ii) to pay to the third-party licensor of the rights sublicensed to us royalty payments for seven years from the first commercial sale of Firdapse™ equal to 7% of net sales (as defined in the license agreement between BioMarin and the third-party licensor) in any calendar year; and (iii) to pay certain milestone payments that BioMarin is obligated to pay (approximately $2.6 million of which will be due upon acceptance by the FDA of a filing of an NDA for Firdapse™ for the treatment of LEMS, and approximately $7.2 million of which will be due on the unconditional approval by the FDA of an NDA for Firdapse™ for the treatment of LEMS). The Company also agreed to share in the cost of certain post-marketing studies being conducted by BioMarin, and, as of December 31, 2014, the Company had paid BioMarin $3.1 million related to expenses in connection with Firdapse™ studies and trials.

On April 15, 2014, effective as of April 8, 2014, the Company and BioMarin entered into Amendment No. 1 to the License Agreement, amending in certain respects the License Agreement, dated October 26, 2012, between the Company and BioMarin. The amendment related to purchases of additional product by the Company from BioMarin, the sharing of data between the parties with respect to clinical trials and studies undertaken by each party and the payment terms for certain joint studies.

AGREEMENTS FOR DRUG DEVELOPMENT, PRE-CLINICAL AND CLINICAL STUDIES. The Company has entered into agreements with contract manufacturers for the manufacture of drug and study placebo for the Company’s trials and studies, with contract research organizations (CRO) to conduct and monitor the Company’s trials and studies and with various entities for laboratories and other testing related to the Company’s trials and studies. The contractual terms of the agreements vary, but most require certain advances as well as payments based on the achievement of milestones. Further, these agreements are cancellable at any time, but obligate the Company to reimburse the providers for any time or costs incurred through the date of termination.

Related Party Transactions

12 Months Ended

Dec. 31, 2014

Related Party Transactions

9.	Related Party Transactions

The Company has entered into consulting agreements with one of the Company’s officers and members of the Company’s Scientific Advisory Board. During the years ended December 31, 2014, 2013 and 2012, the Company paid approximately $10,000, $10,000 and $42,000, respectively, in consulting fees to related parties.

The Company has an employment agreement with its Chief Executive Officer. Under this agreement, the CEO will receive an annual base salary of approximately $453,000 in 2015, and may earn bonus compensation of up to 50% of his salary based on performance. This agreement expires in November 2016.

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References+ Details

Income Taxes

12 Months Ended

Dec. 31, 2014

Income Tax Disclosure [Abstract]

Income Taxes

10.

Income Taxes

As of December 31, 2014 and 2013, the Company had deferred tax assets of approximately $24,895,000 and $19,387,000, respectively, of which approximately $22,898,000 and $17,685,000 represent United States federal and state net operating loss carryforwards and start-up costs. The remaining temporary differences represent non-deductible stock option and equity expense. The related deferred tax asset has a 100% valuation allowance as of December 31, 2014 and 2013, as the Company believes it is more likely than not that the deferred tax asset will not be realized. The change in valuation allowance was approximately $5,508,000, $3,796,000 and $2,151,000 in 2014, 2013 and 2012, respectively. There are no other significant temporary differences. The net operating loss carry-forwards of approximately $40,604,000 as of December 31, 2014 will expire at various dates beginning in 2025 and ending in 2034. If an ownership change, as defined under Internal Revenue Code Section 382, occurs, the use of these carry-forwards may be subject to limitation. The effective tax rate of 0% in all periods presented differs from the statutory rate of 35% due to the valuation allowance and because the Company had no taxable income.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References+ Details

Stockholders' Equity

12 Months Ended

Dec. 31, 2014

Equity [Abstract]

Stockholders' Equity

11.

Stockholders’ Equity

Preferred Stock

The Company has 5,000,000 shares of authorized preferred stock, $0.001 par value per share at December 31, 2014 and 2013. No shares of preferred stock were outstanding at December 31, 2014 and 2013.

Common Stock

The Company has 100,000,000 shares of authorized common stock with a par value of $0.001 per share. At December 31, 2014 and 2013, 69,119,092 and 54,132,937 shares, respectively, of common stock were issued and outstanding. Each holder of common stock is entitled to one vote of each share of common stock held of record on all matters on which stockholders generally are entitled to vote.

2010 Shelf Registration Statement

On December 3, 2010, the Company filed a Shelf Registration Statement on Form S-3 (the 2010 Shelf Registration Statement) with the SEC to sell up to $30 million of common stock and common stock purchase warrants. This registration statement (file No. 333-170945) was declared effective by the SEC on December 15, 2010. The Company has to date conducted the following sales of its securities under the 2010 Shelf Registration Statement:

(a)

On March 8, 2011, the Company filed a prospectus supplement and offered for sale to institutional investors 2,259,943 shares of its common stock at a price of $1.12 per share and received gross proceeds of approximately $2.5 million, before underwriting commission and incurred expenses of approximately $300,000.

(b)

On October 28, 2011, the Company filed a prospectus supplement and offered for sale to institutional investors 3,046,740 shares of its common stock together with common stock purchase warrants to purchase 1,523,370 shares of the Company’s common stock at a price of $1.15 per share and corresponding warrant and received gross proceeds of approximately $3.5 million, before underwriting commission and other expenses totaling approximately $335,000. The warrants issued in this offering, which expire on April 28, 2017 and have an exercise price of $1.30 per share, have been accounted for as a liability. See Note 3.

(c)

On August 28, 2012, the Company filed a prospectus supplement and offered for sale to institutional investors 4,000,000 shares of its common stock together with common stock purchase warrants to purchase 1,200,000 shares of the Company’s common stock at a price of $1.50 per share and corresponding warrant and received gross proceeds of approximately $6.0 million, before underwriting commission and other expenses totaling approximately $440,000. These warrants, which will expire on August 28, 2017 and have an exercise price of $2.08 per share, have been accounted for as equity instruments, since they do not contain features (such as cash settlement or anti-dilution features) that would preclude the Company from accounting for these warrants as equity.

(d)

On September 5, 2013, the Company filed a prospectus supplement and offered for sale to institutional investors 8,800,000 shares of its common stock at a price of $1.72 per share and received gross proceeds of approximately $15.1 million before underwriting commissions and incurred expenses of approximately $1,064,000.

The Company has no further availability under the 2010 Shelf Registration Statement.

2012 Form S-1 Registration Statement

On May 24, 2012, the Company sold 6,000,000 shares of its common stock together with common stock purchase warrants to purchase 6,000,000 shares of the Company’s common stock, at a price of $0.80 per share and corresponding warrant. These securities were issued pursuant to a Form S-1 registration statement that became effective on May 23, 2012 (file no. 333-180617). The Company received gross proceeds of approximately $4.8 million from this offering, before underwriting commission and other expenses totaling approximately $795,000. The May 2012 warrants, which expire five years from their date of issuance and have an exercise price of $1.04 per share, have been accounted for as equity instruments, since they do not contain features (such as net cash settlement or anti-dilution features) that would preclude the Company from accounting for these warrants as equity.

2014 Shelf Registration Statement

On January 31, 2014, the Company filed a Shelf Registration Statement on Form S-3 (the 2014 Shelf Registration Statement) with the SEC to sell up to $100 million of shares of common stock. This registration statement (file No. 333-193699) was declared effective by the SEC on March 19, 2014. The Company has to date conducted the following sales of its securities under the 2014 Shelf Registration Statement:

(a)

On April 3, 2014, the Company filed a prospectus supplement and offered for sale 13,023,750 shares of its common stock at a price of $2.21 per share in an underwritten public offering. The Company received gross proceeds in the public offering of approximately $28.8 million before underwriting commission and incurred expenses of approximately $2.1 million.

(b)

Subsequent to year end, on February 4, 2015, the Company filed a prospectus supplement and offered for sale 11,500,000 shares of its common stock at a price of $3.25 per share in an underwritten public offering. The Company received gross proceeds in the public offering of approximately $37.4 million before underwriting commission and incurred expenses of approximately $2.7 million. (See Note 15).

Following the February 2015 offering, there is approximately $33.8 million available for future sale under the 2014 Shelf Registration Statement. If the Company’s public float (the market value of its common stock held by non-affiliate stockholders) falls below $75 million, the Company will be subject to a further limitation under which it can sell no more than one-third (1/3) of its public float during any 12-month period. Further, the number of shares that the Company can sell at any one time may be limited under certain circumstances to 20% of the outstanding common stock under applicable NASDAQ marketplace rules.

Warrant Exercises

During the years ended December 31, 2014 and 2013, the Company issued an aggregate of 1,262,696 and 3,862,250 shares of its authorized but unissued common stock upon the exercise of previously issued common stock purchase warrants, raising gross proceeds of $1,316,503 and $4,083,300, respectively.

BioMarin convertible promissory note automatic conversion into common stock shares

On October 26, 2012, the Company entered into a note purchase agreement with BioMarin, pursuant to which the Company issued BioMarin a convertible promissory note in the principal amount of $5 million. (See Note 8). The $5 million note automatically converted into 6,666,667 shares of the Company’s common stock (at a price of $0.75 per share) on December 10, 2012.

Stockholder Rights Plan

On September 20, 2011, the Board of Directors approved the Company’s adoption of a Stockholder Rights Plan. Under the Plan, a dividend of one preferred share purchase right (a Right) was declared for each share of common stock of the Company that was outstanding on October 7, 2011. Each Right entitles the holder to purchase from the Company one one-hundredth of a share of Series A Junior Preferred Stock at a purchase price of $7.80, subject to adjustment.

The Rights will trade automatically with the common stock and will not be exercisable until a person or group has become an “acquiring person” by acquiring 17.5% or more of the Company’s outstanding common stock, or a person or group commences, or publicly announces a tender offer that will result in such a person or group owning 17.5% or more of the Company’s outstanding common stock. Upon announcement that any person or group has become an acquiring person, each Right will entitle all rightholders (other than the acquiring person) to purchase, for the exercise price of $7.80, a number of shares of the Company’s common stock having a market value equal to twice the exercise price. Rightholders would also be entitled to purchase common stock of the acquiring person having a value of twice the exercise price if, after a person had become an acquiring person, the Company were to enter into certain mergers or other transactions. If any person becomes an acquiring person, the Board of Directors may, at its option and subject to certain limitations, exchange one share of common stock for each Right.

The Rights have certain anti-takeover effects, in that they would cause substantial dilution to a person or group that attempts to acquire a significant interest in the Company on terms not approved by the Board of Directors. In the event that the Board of Directors determines a transaction to be in the best interests of the Company and its stockholders, the Board of Directors may redeem the Rights for $0.001 per share at any time prior to a person or group becoming an acquiring person. The Rights will expire on September 20, 2016, unless earlier redeemed or exchanged.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 4

-Subparagraph (SAB TOPIC 4.C)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Article 4

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section C

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(d),(e))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Preferred Stock

-URI http://asc.fasb.org/extlink&oid=6521494

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 17: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 18: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph d

-Article 4

Reference 19: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

+ Details

Stock Compensation Plans

12 Months Ended

Dec. 31, 2014

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Stock Compensation Plans

12.

Stock Compensation Plans

The Company issues options, restricted stock, stock appreciation rights and restricted stock units (collectively, the “Awards”) to employees, directors, consultants and scientific advisors of the Company under the 2006 and 2014 Stock Incentive Plans (the 2006 Plan and the 2014 Plan or collectively, the Plans). Prior to July 2006, the Company granted options pursuant to written agreements to purchase an aggregate of 2,352,254 shares of common stock. At December 31, 2014, no shares remain available for future issuance under the 2006 Plan. On February 27, 2014, the Company’s Board of Directors approved the adoption of the “Catalyst Pharmaceutical Partners, Inc. 2014 Stock Incentive Plan”. The 2014 Plan became effective upon stockholder approval of the 2014 Plan at the Company’s 2014 Annual Meeting of Stockholders held on May 15, 2014. Under the Plan, 4,000,000 shares were reserved for issuance under the 2014 Plan and as of December 31, 2014, 2,640,000 shares remain available for future issuance under the 2014 Plan.

Stock Options

The Company has granted stock options to employees, officers, directors, scientific advisors and consultants generally at exercise prices equal to the market price of the common stock at grant date. Option awards generally vest over a period of 2 to 4 years of continuous service and have contractual terms from 5 to 10 years. Certain awards provide for accelerated vesting if there is a change in control. The Company issues new shares as shares are required to be delivered upon exercise of outstanding stock options.

During the year ended December 31, 2014, options to purchase 580,000 shares of the Company’s common stock were exercised with proceeds of $522,000. Further, during the year ended December 31, 2014, options to purchase 185,000 shares of the Company’s common stock were exercised on a “cashless” basis, resulting in the issuance of an aggregate of 119,709 shares of the Company’s common stock.

During the year ended December 31, 2013, options to purchase 50,000 shares of the Company’s common stock were exercised with proceeds of $23,500.

During the years ended December 31, 2014, 2013 and 2012 the Company recorded non-cash stock-based compensation expense related to stock options totaling $767,838, $175,855 and $340,039, respectively.

During the year ended December 31, 2014, the Company granted five and seven-year options to purchase an aggregate of 1,305,000 shares of the Company’s common stock to certain of the Company’s officers, employees, directors, and consultants. During the years ended December 31, 2013 and 2012, the Company granted five-year options to purchase an aggregate of 115,000 shares and 975,000 shares, respectively, of the Company’s common stock to certain of the Company’s officers, employees, directors and consultants.

Stock option activity under the Company’s written stock option agreements and the Plans for the year ended December 31, 2014 is summarized as follows:


	Number of Options			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value
Outstanding at beginning of year		3,428,906		$	0.80
Granted		1,305,000			3.08
Exercised		(765,000	)		0.90
Forfeited or cancelled		(50,000	)		2.71
Expired		(34,296	)		3.28

Outstanding at end of year		3,884,610		$	1.50		3.29	$	5,897,040

Exercisable at end of year		2,687,943		$	0.86		1.91	$	5,703,106

Other information pertaining to stock option activity during the years ended December 31, 2014, 2013 and 2012 was as follows:


	2014		2013		2012
Weighted–average fair value of granted stock options	$	2.41	$	0.48	$	0.32
Total fair value of vested stock options	$	409,476	$	166,633	$	348,815
Total intrinsic value of exercised stock options	$	1,339,100	$	17,975	$	40,050

The following table summarizes information about the Company’s options outstanding at December 31, 2014:


	Options Outstanding						Options Exercisable
Range of Exercise Prices	Number Outstanding		Weighted Average Remaining Contractual Life (Years)		Weighted Average Exercise Price		Number Exercisable		Weighted Average Remaining Contractual Life (Years)		Weighted Average Exercise Price
$0.47		1,000,000		2.97	$	0.47		950,000		2.95	$	0.47
$0.69		729,610		0.17	$	0.69		729,610		0.17	$	0.69
$0.85		40,000		3.39	$	0.85		13,333		3.39	$	0.85
$1.07- $1.09		860,000		1.48	$	1.08		860,000		1.48	$	1.08
$2.34- $2.35		30,000		4.39	$	2.35		10,000		4.24	$	2.34
$3.03- $3.12		1,225,000		6.67	$	3.12		125,000		6.66	$	3.12

		3,884,610		3.29	$	1.50		2,687,943		1.91	$	0.86

As of December 31, 2014, there was approximately $2,400,000 of unrecognized compensation expense related to non-vested stock option awards granted under the Plans. That cost is expected to be recognized over a weighted average period of approximately 2.5 years.

The Company utilizes the Black-Scholes option-pricing model to determine the fair value of stock options on the date of grant. This model derives the fair value of stock options based on certain assumptions related to the expected stock price volatility, expected option life, risk-free interest rate and dividend yield. Expected volatility is based on reviews of historical volatility of the Company’s common stock. The estimated expected option life is based upon estimated employee exercise patterns and considers whether and the extent to which the options are in-the-money. The Company estimates the expected option life for options granted to employees and directors based upon the simplified method. Under this method, the expected life is presumed to be the mid-point between the vesting date and the end of the contractual term. The Company will continue to use the simplified method until it has sufficient historical exercise data to estimate the expected life of the options. The risk-free interest rate assumption is based upon the U.S. Treasury yield curve appropriate for the estimated life of the stock options awards. The expected dividend rate is zero. Stock–based compensation expense also includes an estimate, which the Company makes at grant date, of the number of awards that are expected to be forfeited. The Company revises this estimate in subsequent periods if actual forfeitures differ from those estimates.

Assumptions used during the years were as follows:


	Year ended December 31,
	2014			2013			2012
Risk free interest rate		1.18% to 2.03	%		0.45% to 0.53	%		0.28% to 0.66	%
Expected term		3 to 7 years			3 years			3 to 5 years
Expected volatility		115	%		137	%		120	%
Expected dividend yield		—	%		—	%		—	%
Expected forfeiture rate		—	%		—	%		—	%

Restricted Stock Units

Under the 2014 Plan, participants may be granted restricted stock units, each of which represents a conditional right to receive shares of common stock in the future. The restricted stock units granted under this plan generally vest ratably over a three to four-year period. Upon vesting, the restricted stock units will convert into an equivalent number of shares of common stock. The amount of expense relating to the restricted stock units is based on the closing market price of the Company’s common stock on the date of grant and is amortized on a straight-line basis over the requisite service period. There was no restricted stock unit activity during 2013 or 2012. Restricted stock unit activity during 2014 was as follows:


	2014
	Number of Restricted Stock Units		Weighted Average Grant Date Fair Value
Nonvested balance at beginning of year		—		—
Granted		80,000	$	2.83
Vested		—		—
Forfeited		—		—

Nonvested balance at end of year		80,000	$	2.83

During the years ended December 31, 2014, 2013 and 2012, the Company recorded non-cash stock-based compensation expense related to restricted stock units totaling $10,131, $0 and $0, respectively.

- Definition

The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.

+ References+ Details

Benefit Plan

12 Months Ended

Dec. 31, 2014

Compensation and Retirement Disclosure [Abstract]

Benefit Plan

13.

Benefit Plan

The Company maintains an employee savings plan pursuant to Section 401(k) of the Internal Revenue Code covering all eligible employees. Subject to certain dollar limits, eligible employees may contribute up to 15% of their pre-tax annual compensation to the plan. The Company has elected to make discretionary matching contributions of employee contributions up to 4% of an employee’s gross salary. For the years ended December 31, 2014, 2013 and 2012, the Company’s matching contributions were approximately $44,000, $30,000 and $28,000, respectively.

- Definition

The entire disclosure for pension and other postretirement benefits.

+ References+ Details

Quarterly Financial Information (unaudited)

12 Months Ended

Dec. 31, 2014

Quarterly Financial Information Disclosure [Abstract]

Quarterly Financial Information (unaudited)

14.

Quarterly Financial Information (unaudited)

The following table presents unaudited supplemental quarterly financial information for the years ended December 31, 2014 and 2013:


	Quarter Ended
	March 31, 2014			June 30, 2014			September 30, 2014			December 31, 2014
Revenues	$	—		$	—		$	—		$	—
Loss from operations		(3,508,365	)		(2,990,173	)		(4,109,029	)		(3,983,861	)
Change in fair value of warrants liability		(335,514	)		(223,591	)		(906,787	)		472,026
Net loss		(3,811,119	)		(3,198,020	)		(5,009,892	)		(3,490,030	)
Loss per share—basic and diluted	$	(0.07	)	$	(0.05	)	$	(0.07	)	$	(0.05	)

	Quarter Ended
	March 31, 2013			June 30, 2013			September 30, 2013			December 31, 2013
Revenues	$	—		$	—		$	—		$	—
Loss from operations		(1,705,430	)		(2,653,529	)		(3,245,776	)		(2,706,923	)
Change in fair value of warrants liability		(45,326	)		(498,587	)		(2,676,601	)		1,330,155
Net loss		(1,744,289	)		(3,143,590	)		(5,912,059	)		(1,354,658	)
Loss per share—basic and diluted	$	(0.04	)	$	(0.08	)	$	(0.13	)	$	(0.03	)

Quarterly basic and diluted net loss per common share were computed independently for each quarter and do not necessarily total to the full year basic and diluted net loss per common share.

- Definition

The entire disclosure for the quarterly financial data in the annual financial statements. The disclosure may include a tabular presentation of financial information for each fiscal quarter for the current and previous year, including revenues, gross profit, income or loss before extraordinary items and earnings per share data. It also includes an indication if the information in the note is unaudited, comments on the aggregate effect of year-end adjustments, and an explanation of matters or transactions that affect comparability or are pertinent to an understanding of the information furnished.

+ References+ Details

Subsequent Event

12 Months Ended

Dec. 31, 2014

Subsequent Events [Abstract]

Subsequent Event

15.

Subsequent Event

Subsequent to year-end, the Company issued an aggregate of 152,174 shares of its authorized but unissued common stock upon the exercise of previously issued common stock purchase warrants that were issued in October 2011, raising gross proceeds of approximately $198,000. Additionally, subsequent to year end, stock options to purchase 829,608 shares of the Company’s common stock were exercised on a “cashless” basis, resulting in the issuance of an aggregate of 673,583 shares of the Company’s common stock.

Basis of Presentation and Significant Accounting Policies (Policies)

12 Months Ended

Dec. 31, 2014

Accounting Policies [Abstract]

USE OF ESTIMATES

CASH AND CASH EQUIVALENTS

CERTIFICATES OF DEPOSIT

SHORT-TERM INVESTMENTS

PREPAID EXPENSES AND OTHER CURRENT ASSETS

PROPERTY AND EQUIPMENT

OPERATING LEASES

FAIR VALUE OF FINANCIAL INSTRUMENTS

FAIR VALUE MEASUREMENTS


			Fair Value Measurements at Reporting Date Using
	Balances as of December 31, 2014		Quoted Prices in Active Markets for Identical Assets/Liabilities (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Money market funds	$	7,053,310	$	7,053,310	$	—	$	—

Certificates of deposit	$	3,715,383	$	—	$	3,715,383	$	—

Short-term investments	$	26,462,962	$	26,462,962	$	—	$	—

Warrants liability	$	2,794,891	$	—	$	—	$	2,794,891


			Fair Value Measurements at Reporting Date Using
	Balances as of December 31, 2013		Quoted Prices in Active Markets for Identical Assets/Liabilities (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Money market funds	$	25,693	$	25,693	$	—	$	—

Certificates of deposit	$	4,011,576	$	—	$	4,011,576	$	—

Short-term investments	$	17,483,062	$	17,483,062	$	—	$	—

Warrants liability	$	1,819,562	$	—	$	—	$	1,819,562

WARRANTS LIABILITY

RESEARCH AND DEVELOPMENT

STOCK-BASED COMPENSATION

For the years ended December 31, 2014, 2013 and 2012, the Company recorded stock-based compensation expense as follows:


	2014		2013		2012
Research and development	$	133,862	$	84,728	$	100,221
General and administrative		644,107		91,127		239,818

Total stock-based compensation	$	777,969	$	175,855	$	340,039

CONCENTRATION OF CREDIT RISK

INCOME TAXES

COMPREHENSIVE INCOME (LOSS)

NET INCOME (LOSS) PER SHARE


	2014		2013		2012
Options to purchase common stock		3,884,610		3,428,906		3,650,535
Warrants to purchase common stock		3,585,924		4,848,620		8,710,870
Unvested restricted stock		80,000		—		—

Potential equivalent common stock excluded		7,550,534		8,277,526		12,361,405

SEGMENT INFORMATION

q.	SEGMENT INFORMATION. Management has determined that the Company operates in one reportable segment, which is the development and commercialization of pharmaceutical products.

RECLASSIFICATIONS

r.	RECLASSIFICATIONS. Certain prior year amounts in the financial statements have been reclassified to conform to the current year presentation.

RECENTLY ISSUED ACCOUNTING STANDARDS

Basis of Presentation and Significant Accounting Policies (Tables)

12 Months Ended

Dec. 31, 2014

Accounting Policies [Abstract]

Fair Value Measurement Specific to Assets or Liability

The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment, and considers factors specific to the asset or liability.


			Fair Value Measurements at Reporting Date Using
	Balances as of December 31, 2014		Quoted Prices in Active Markets for Identical Assets/Liabilities (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Money market funds	$	7,053,310	$	7,053,310	$	—	$	—

Certificates of deposit	$	3,715,383	$	—	$	3,715,383	$	—

Short-term investments	$	26,462,962	$	26,462,962	$	—	$	—

Warrants liability	$	2,794,891	$	—	$	—	$	2,794,891


			Fair Value Measurements at Reporting Date Using
	Balances as of December 31, 2013		Quoted Prices in Active Markets for Identical Assets/Liabilities (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Money market funds	$	25,693	$	25,693	$	—	$	—

Certificates of deposit	$	4,011,576	$	—	$	4,011,576	$	—

Short-term investments	$	17,483,062	$	17,483,062	$	—	$	—

Warrants liability	$	1,819,562	$	—	$	—	$	1,819,562

Stock-Based Compensation Expense

For the years ended December 31, 2014, 2013 and 2012, the Company recorded stock-based compensation expense as follows:


	2014		2013		2012
Research and development	$	133,862	$	84,728	$	100,221
General and administrative		644,107		91,127		239,818

Total stock-based compensation	$	777,969	$	175,855	$	340,039

Potential Shares Excluded from Determination of Basic and Diluted Net Loss Per Share

The potential shares, which are excluded from the determination of basic and diluted net loss per share as their effect is anti-dilutive, are as follows, for the years ended December 31, 2014, 2013 and 2012:


	2014		2013		2012
Options to purchase common stock		3,884,610		3,428,906		3,650,535
Warrants to purchase common stock		3,585,924		4,848,620		8,710,870
Unvested restricted stock		80,000		—		—

Potential equivalent common stock excluded		7,550,534		8,277,526		12,361,405

Warrants Liability, at Fair Value (Tables)

12 Months Ended

Dec. 31, 2014

Summary of Company's Warrants Liability Activity

The following table rolls forward the fair value of the Company’s warrants liability activity for the years ended December 31, 2014, 2013 and 2012:


	2014			2013			2012
Fair value, beginning of period	$	1,819,562		$	498,587		$	1,645,240
Issuance of warrants		—			—			—
Exercise of warrants		(18,537	)		(569,384	)		(16,875	)
Change in fair value		993,866			1,890,359			(1,129,778	)

Fair value, end of period	$	2,794,891		$	1,819,562		$	498,587

Warrant [Member]

Summary of Assumptions Used in Black-Scholes Model to Calculate Fair Value of Warrants Liability

This liability is subject to fair value mark-to-market adjustment each reporting period. The calculated value of the 2011 warrants liability was determined using the Black-Scholes option-pricing model with the following assumptions:


	December 31, 2014			December 31, 2013
Risk free interest rate		0.81	%		0.94	%
Expected term		2.34 years			3.34 years
Expected volatility		112	%		108	%
Expected dividend yield		0	%		0	%
Expected forfeiture rate		0	%		0	%

- Definition

Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.

+ References+ Details

Prepaid Expenses and Other Current Assets (Tables)

12 Months Ended

Dec. 31, 2014

Text Block [Abstract]

Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consist of the following as of December 31:


	2014		2013
Insurance recoverable (see Note 7)	$	3,500,000	$	—
Prepaid research fees		571,428		1,334,149
Prepaid insurance		385,496		219,651
Prepaid subscriptions fees		30,495		24,643
Prepaid offering costs		20,029		—
Prepaid rent		10,870		7,848
Other		34,380		23,151

Total prepaid expenses	$	4,552,698	$	1,609,442

Property and Equipment (Tables)

12 Months Ended

Dec. 31, 2014

Property, Plant and Equipment [Abstract]

Property and Equipment, Net

Property and equipment, net consists of the following as of December 31:


	2014			2013
Computer equipment	$	95,754		$	81,551
Furniture and equipment		88,816			51,523

		184,570			133,074
Less: Accumulated depreciation		(113,193	)		(92,446	)

Total property and equipment, net	$	71,377		$	40,628

Accrued Expenses and Other Liabilities (Tables)

12 Months Ended

Dec. 31, 2014

Payables and Accruals [Abstract]

Schedule of Accrued Expenses and Other Liabilities

Accrued expenses and other liabilities consist of the following as of December 31:


	2014		2013
Accrued settlement liability (see Note 7)	$	3,500,000	$	—
Accrued pre-clinical and clinical trial expenses		333,928		1,083,749
Accrued professional fees		43,973		117,240
Accrued compensation and benefits		31,956		14,539
Accrued license fees		115,000		65,000
Deferred rent		4,158		2,746
Other		11,801		5,546

Current accrued expenses and other liabilities		4,040,816		1,288,820
Deferred rent—non-current		15,839		19,131

Non-current accrued expenses and other liabilities		15,839		19,131

Total accrued expenses and other liabilities	$	4,056,655	$	1,307,951

Commitments and Contingencies (Tables)

12 Months Ended

Dec. 31, 2014

Commitments and Contingencies Disclosure [Abstract]

Future Minimum Lease Payments under Operating Lease Agreement

As of December 31, 2014, future minimum lease payments under the operating lease agreement are as follows:


2015	$	103,902
2016		107,010
2017		100,076

	$	310,988

Stock Compensation Plans (Tables)

12 Months Ended

Dec. 31, 2014

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Summary of Stock Option Activity under the Company's Written Stock Option Agreements and the Plans

Stock option activity under the Company’s written stock option agreements and the Plans for the year ended December 31, 2014 is summarized as follows:


	Number of Options			Weighted Average Exercise Price		Weighted Average Remaining Contractual Term (in years)		Aggregate Intrinsic Value
Outstanding at beginning of year		3,428,906		$	0.80
Granted		1,305,000			3.08
Exercised		(765,000	)		0.90
Forfeited or cancelled		(50,000	)		2.71
Expired		(34,296	)		3.28

Outstanding at end of year		3,884,610		$	1.50		3.29	$	5,897,040

Exercisable at end of year		2,687,943		$	0.86		1.91	$	5,703,106

Schedule of Other Information Pertaining to Stock Option Activity

Other information pertaining to stock option activity during the years ended December 31, 2014, 2013 and 2012 was as follows:


	2014		2013		2012
Weighted–average fair value of granted stock options	$	2.41	$	0.48	$	0.32
Total fair value of vested stock options	$	409,476	$	166,633	$	348,815
Total intrinsic value of exercised stock options	$	1,339,100	$	17,975	$	40,050

Summary of Company's Stock Options Outstanding

The following table summarizes information about the Company’s options outstanding at December 31, 2014:


	Options Outstanding						Options Exercisable
Range of Exercise Prices	Number Outstanding		Weighted Average Remaining Contractual Life (Years)		Weighted Average Exercise Price		Number Exercisable		Weighted Average Remaining Contractual Life (Years)		Weighted Average Exercise Price
$0.47		1,000,000		2.97	$	0.47		950,000		2.95	$	0.47
$0.69		729,610		0.17	$	0.69		729,610		0.17	$	0.69
$0.85		40,000		3.39	$	0.85		13,333		3.39	$	0.85
$1.07- $1.09		860,000		1.48	$	1.08		860,000		1.48	$	1.08
$2.34- $2.35		30,000		4.39	$	2.35		10,000		4.24	$	2.34
$3.03- $3.12		1,225,000		6.67	$	3.12		125,000		6.66	$	3.12

		3,884,610		3.29	$	1.50		2,687,943		1.91	$	0.86

Summary of Stock Options Awards Based on Certain Assumptions

Assumptions used during the years were as follows:


	Year ended December 31,
	2014			2013			2012
Risk free interest rate		1.18% to 2.03	%		0.45% to 0.53	%		0.28% to 0.66	%
Expected term		3 to 7 years			3 years			3 to 5 years
Expected volatility		115	%		137	%		120	%
Expected dividend yield		—	%		—	%		—	%
Expected forfeiture rate		—	%		—	%		—	%

Summary of Restricted Stock Unit Activity

Restricted stock unit activity during 2014 was as follows:


	2014
	Number of Restricted Stock Units		Weighted Average Grant Date Fair Value
Nonvested balance at beginning of year		—		—
Granted		80,000	$	2.83
Vested		—		—
Forfeited		—		—

Nonvested balance at end of year		80,000	$	2.83

Quarterly Financial Information (unaudited) (Tables)

12 Months Ended

Dec. 31, 2014

Quarterly Financial Information Disclosure [Abstract]

Schedule of Quarterly Financial Information

The following table presents unaudited supplemental quarterly financial information for the years ended December 31, 2014 and 2013:


	Quarter Ended
	March 31, 2014			June 30, 2014			September 30, 2014			December 31, 2014
Revenues	$	—		$	—		$	—		$	—
Loss from operations		(3,508,365	)		(2,990,173	)		(4,109,029	)		(3,983,861	)
Change in fair value of warrants liability		(335,514	)		(223,591	)		(906,787	)		472,026
Net loss		(3,811,119	)		(3,198,020	)		(5,009,892	)		(3,490,030	)
Loss per share—basic and diluted	$	(0.07	)	$	(0.05	)	$	(0.07	)	$	(0.05	)

	Quarter Ended
	March 31, 2013			June 30, 2013			September 30, 2013			December 31, 2013
Revenues	$	—		$	—		$	—		$	—
Loss from operations		(1,705,430	)		(2,653,529	)		(3,245,776	)		(2,706,923	)
Change in fair value of warrants liability		(45,326	)		(498,587	)		(2,676,601	)		1,330,155
Net loss		(1,744,289	)		(3,143,590	)		(5,912,059	)		(1,354,658	)
Loss per share—basic and diluted	$	(0.04	)	$	(0.08	)	$	(0.13	)	$	(0.03	)

Organization and Description of Business - Additional Information (Detail) (2014 Shelf Registration Statement [Member], USD $) In Millions, except Share data, unless otherwise specified		0 Months Ended
	Jan. 31, 2014	Apr. 03, 2014 Underwritten Public Offering [Member]	Feb. 04, 2015 Underwritten Public Offering [Member] Subsequent Event [Member]
Organization And Description Of Business [Line Items]
Maximum dollar amount of common stock to be issued under shelf registration statement	$ 100
Net proceeds from issuance of common stock		$ 26.7	$ 34.7
Number of common stock sold in offering		13,023,750	11,500,000

Basis of Presentation and Significant Accounting Policies - Additional Information (Detail) (USD $)	12 Months Ended			0 Months Ended			1 Months Ended			12 Months Ended				12 Months Ended				12 Months Ended
	Dec. 31, 2014 Segment	Dec. 31, 2013	Dec. 31, 2012	Oct. 28, 2011 2010 Shelf Registration Statement [Member]	Aug. 28, 2012 2010 Shelf Registration Statement [Member]	Oct. 28, 2011 2010 Shelf Registration Statement [Member]	Oct. 31, 2011 October 28, 2011 Warrants [Member] 2010 Shelf Registration Statement [Member]	Dec. 31, 2014 October 28, 2011 Warrants [Member] 2010 Shelf Registration Statement [Member]	Dec. 31, 2013 October 28, 2011 Warrants [Member] 2010 Shelf Registration Statement [Member]	Dec. 31, 2014 Computer Equipment [Member]	Dec. 31, 2014 Maximum [Member]	Dec. 31, 2013 Maximum [Member]	Dec. 31, 2012 Maximum [Member]	Dec. 31, 2014 Maximum [Member] Furniture and Equipment [Member]	Dec. 31, 2014 Minimum [Member]	Dec. 31, 2013 Minimum [Member]	Dec. 31, 2012 Minimum [Member]	Dec. 31, 2014 Minimum [Member] Furniture and Equipment [Member]
Summary Of Basis Of Presentation And Significant Accounting Policies [Line Items]
Maximum maturity period of cash and cash equivalent	3 months
Maturity period of certificates of deposit											1 year				3 months
Useful life of assets										3 years				6 years				3 years
Deferred rent in accrued expenses and other liabilities	$ 19,997	$ 21,877
Warrants issued in offering				1,523,370			1,523,370
Warrants outstanding								1,242,174	1,254,870
Minimum amortization period of compensation cost on straight line basis	3 years
Maximum amortization period of compensation cost on straight line basis	7 years
Stock option exercise price range, Minimum	$ 0.47	$ 0.47	$ 0.47
Stock option exercise price range, Maximum	$ 3.12	$ 6.00	$ 6.00
Potentially dilutive warrants to purchase common stock					$ 2.08	$ 1.30					$ 2.08	$ 2.08	$ 2.08		$ 1.04	$ 1.04	$ 1.04
Number of reportable segment	1

Basis of Presentation and Significant Accounting Policies - Fair Value Measurement Specific to Assets or Liability (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market funds	$ 7,053,310	$ 25,693
Certificates of deposit	3,715,383	4,011,576
Short-term investments	26,462,962	17,483,062
Warrants liability	2,794,891	1,819,562
Quoted Prices in Active Markets for Identical Assets/Liabilities (Level 1) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Money market funds	7,053,310	25,693
Short-term investments	26,462,962	17,483,062
Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Certificates of deposit	3,715,383	4,011,576
Significant Unobservable Inputs (Level 3) [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants liability	$ 2,794,891	$ 1,819,562

Basis of Presentation and Significant Accounting Policies - Potential Shares Excluded from Determination of Basic and Diluted Net Loss Per Share (Detail)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential equivalent common stock excluded	7,550,534	8,277,526	12,361,405
Options to Purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential equivalent common stock excluded	3,884,610	3,428,906	3,650,535
Warrants to Purchase Common Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential equivalent common stock excluded	3,585,924	4,848,620	8,710,870
Unvested Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potential equivalent common stock excluded	80,000

- Definition

Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.

+ References+ Details

Warrants Liability, at Fair Value - Additional Information (Detail) (USD $)	1 Months Ended	12 Months Ended
	Oct. 31, 2011	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Class of Warrant or Right [Line Items]
Recognition of warrants fair value at date of issuance		$ 0	$ 0	$ 0
Proceeds from exercise of warrants		1,316,503	4,083,300	16,249
October 28, 2011 Warrants [Member] \| Warrant Liability [Member]
Class of Warrant or Right [Line Items]
Recognition of warrants fair value at date of issuance	1,300,000
Number of warrants exercised during the period		12,696	256,000	12,500
Proceeds from exercise of warrants		$ 16,504	$ 332,800	$ 16,249

Warrants Liability, at Fair Value - Summary of Assumptions Used in Black-Scholes Model to Calculate Fair Value of Warrants Liability (Detail) (Warrant [Member])	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Warrant [Member]
Fair Value Inputs Assets Liabilities Quantitative Information [Line Items]
Risk free interest rate	0.81%	0.94%
Expected term	2 years 4 months 2 days	3 years 4 months 2 days
Expected volatility	112.00%	108.00%
Expected dividend yield	0.00%	0.00%
Expected forfeiture rate	0.00%	0.00%

Warrants Liability, at Fair Value - Summary of Company's Warrants Liability Activity (Detail) (USD $)	3 Months Ended								12 Months Ended
	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Fair Value Disclosures [Abstract]
Fair value, beginning of period				$ 1,819,562				$ 498,587	$ 1,819,562	$ 498,587	$ 1,645,240
Issuance of warrants									0	0	0
Exercise of warrants									(18,537)	(569,384)	(16,875)
Change in fair value	472,026	(906,787)	(223,591)	(335,514)	1,330,155	(2,676,601)	(498,587)	(45,326)	993,866	1,890,359	(1,129,778)
Fair value, end of period	$ 2,794,891				$ 1,819,562				$ 2,794,891	$ 1,819,562	$ 498,587

Prepaid Expenses and Other Current Assets - Prepaid Expenses and Other Current Assets (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]
Insurance recoverable	$ 3,500,000
Prepaid research fees	571,428	1,334,149
Prepaid insurance	385,496	219,651
Prepaid subscriptions fees	30,495	24,643
Prepaid offering costs	20,029
Prepaid rent	10,870	7,848
Other	34,380	23,151
Total prepaid expenses	$ 4,552,698	$ 1,609,442

- Definition

Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.

+ References+ Details

- Definition

Amount of asset related to consideration paid in advance for rent that provides economic benefits within a future period of one year or the normal operating cycle, if longer.

+ References+ Details

Property and Equipment - Property and Equipment, Net (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 184,570	$ 133,074
Less: Accumulated depreciation	(113,193)	(92,446)
Total property and equipment, net	71,377	40,628
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	95,754	81,551
Furniture and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 88,816	$ 51,523

Accrued Expenses and Other Liabilities - Schedule of Accrued Expenses and Other Liabilities (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Payables and Accruals [Abstract]
Accrued settlement liability	$ 3,500,000
Accrued pre-clinical and clinical trial expenses	333,928	1,083,749
Accrued professional fees	43,973	117,240
Accrued compensation and benefits	31,956	14,539
Accrued license fees	115,000	65,000
Deferred rent	4,158	2,746
Other	11,801	5,546
Current accrued expenses and other liabilities	4,040,816	1,288,820
Deferred rent-non-current	15,839	19,131
Non-current accrued expenses and other liabilities	15,839	19,131
Total accrued expenses and other liabilities	$ 4,056,655	$ 1,307,951

Commitments and Contingencies - Future Minimum Lease Payments under Operating Lease Agreement (Detail) (USD $)	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
2015	$ 103,902
2016	107,010
2017	100,076
Total	$ 310,988

Commitments and Contingencies - Additional Information (Detail) (USD $)	1 Months Ended	2 Months Ended	12 Months Ended
	Oct. 31, 2013 Lawsuits	Nov. 30, 2013 Lawsuits	Dec. 31, 2014 Lawsuits	Dec. 31, 2013	Dec. 31, 2012
Commitments and Contingencies Disclosure [Abstract]
Extension period of original lease term			5 years
Rent expense			$ 90,163	$ 69,930	$ 65,310
Number of lawsuits filed	3	3
Number of lawsuits dismissed			2
Date of dismissal of lawsuits			Jan. 03, 2014
Number of days granted to plaintiffs to file an amended complaint			20 days
Accrued settlement liability			$ 3,500,000

Agreements (NORTHWESTERN UNIVERSITY) - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
License Agreement [Line Items]
Accrued license fees	$ 115,000	$ 65,000
Northwestern License Agreement [Member]
License Agreement [Line Items]
License fee paid	251,590
Accrued license fees	115,000	65,000
Future milestone payment	$ 150,000

Agreements (BIOMARIN) - Additional Information (Detail) (License Agreement with BioMarin [Member], USD $)	12 Months Ended
	Dec. 31, 2014	Oct. 26, 2012
License Agreement [Line Items]
Date on which strategic collaboration is entered into	Oct. 26, 2012
Investment pursuant to strategic collaboration		$ 5,000,000
Investment solely for purpose of developing Firdapse		5,000,000
Minimum amount to be spent for Firdapse Phase 3 trial	5,000,000
Estimated time from entering license agreement to completion of double blind treatment phase period of Firdapse phase three trial	24 months
Royalty agreement period	7 years
Net sales royalty threshold	100,000,000
Milestone payment due upon NDA acceptance	2,600,000
Milestone payment due upon NDA approval	7,200,000
Costs paid for Firdapse joint studies	$ 3,100,000
Minimum [Member]
License Agreement [Line Items]
Percentage of royalty on net sales	7.00%
Maximum [Member]
License Agreement [Line Items]
Percentage of royalty on net sales	10.00%

Related Party Transactions - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Consulting Agreements [Member]
Related Party Transaction [Line Items]
Consulting fees to Company officer and members of the Scientific Advisory Board	$ 10,000	$ 10,000	$ 42,000
CEO Employment Agreement [Member]
Related Party Transaction [Line Items]
Annual base salary of CEO	$ 453,000
Expiration date of employment agreement	2016-11
CEO potential performance based bonus compensation as a percentage of base salary	50.00%

Income Taxes - Additional Information (Detail) (USD $)	12 Months Ended
Income Taxes - Additional Information (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income Tax Disclosure [Abstract]
Deferred tax assets	$ 24,895,000	$ 19,387,000
Net operating loss carryforward and start-up costs	22,898,000	17,685,000
Valuation allowance	100.00%	100.00%
Change in valuation allowance	5,508,000	3,796,000	2,151,000
Net operating loss carryforwards	$ 40,604,000
Net operating loss carryforwards expiration date	Beginning in 2025 and ending in 2034
Effective tax rate	0.00%
Statutory rate	35.00%

Stockholders' Equity (Preferred Stock and Common Stock) - Additional Information (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Equity [Abstract]
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares outstanding	0	0
Common stock, shares authorized	100,000,000	100,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares issued	69,119,092	54,132,937
Common stock, shares outstanding	69,119,092	54,132,937

Stockholders' Equity (2010 Shelf Registration Statement) - Additional Information (Detail) (2010 Shelf Registration Statement [Member], USD $)	0 Months Ended
	Sep. 05, 2013	Aug. 28, 2012	Oct. 28, 2011	Mar. 08, 2011	Sep. 05, 2013	Aug. 28, 2012	Oct. 28, 2011	Mar. 08, 2011	Dec. 03, 2010
2010 Shelf Registration Statement [Member]
Stockholders' Equity [Line Items]
Maximum dollar amount of common stock to be issued under shelf registration statement									$ 30,000,000
Number of common stock sold in offering	8,800,000	4,000,000	3,046,740	2,259,943
Common stock offer price per share					$ 1.72			$ 1.12
Proceeds from issuance of common stock ,gross	15,100,000			2,500,000
Offering expenses	1,064,000	440,000	335,000	300,000
Warrants issued in offering			1,523,370
Common stock and warrants offer price per share						$ 1.50	$ 1.15
Gross proceeds from issuance of common stock and warrants		$ 6,000,000	$ 3,500,000
Warrants exercise price						$ 2.08	$ 1.30
Class of warrant or right expiration date		Aug. 28, 2017	Apr. 28, 2017
Number of warrants sold (in shares)						1,200,000

Stockholders' Equity (2012 Form S-1 Registration Statement) - Additional Information (Detail) (2012 Form S-1 Registration Statement [Member], USD $)	0 Months Ended
	May 24, 2012	May 24, 2012
2012 Form S-1 Registration Statement [Member]
Stockholders' Equity [Line Items]
Number of common stock sold in offering	6,000,000
Number of warrants sold (in shares)		6,000,000
Common stock and warrants offer price per share		$ 0.80
Gross proceeds from issuance of common stock and warrants	$ 4,800,000
Offering expenses	$ 795,000
Warrants exercise price		$ 1.04
Warrant expiration period	5 years

Stockholders' Equity (2014 Shelf Registration Statement) - Additional Information (Detail) (2014 Shelf Registration Statement [Member], USD $)		1 Months Ended	0 Months Ended		0 Months Ended
	Jan. 31, 2014	Feb. 28, 2015 Subsequent Event [Member]	Apr. 03, 2014 Underwritten Public Offering [Member]	Apr. 03, 2014 Underwritten Public Offering [Member]	Feb. 04, 2015 Underwritten Public Offering [Member] Subsequent Event [Member]	Feb. 04, 2015 Underwritten Public Offering [Member] Subsequent Event [Member]
Stockholders' Equity [Line Items]
Maximum dollar amount of common stock to be issued under shelf registration statement	$ 100,000,000
Number of common stock sold in offering			13,023,750		11,500,000
Common stock issued, price per share				$ 2.21		$ 3.25
Gross proceeds from issuance of common stock			28,800,000		37,400,000
Offering expenses			2,100,000		2,700,000
Value of common stock available for future sale		33,800,000
Value of public float below which agreed limitation arise		$ 75,000,000
Maximum percentage of outstanding shares that company can sell under shelf registration statement		20.00%

Stockholders' Equity (Warrant Exercises and BioMarin convertible promissory note automatic conversion into common stock shares) - Additional Information (Detail) (USD $)	12 Months Ended			0 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 10, 2012 BioMarin Convertible Promissory Note [Member]	Dec. 10, 2012 BioMarin Convertible Promissory Note [Member]
Stockholders' Equity [Line Items]
Issuance of common stock for warrant exercises	1,262,696	3,862,250
Proceeds from exercise of warrants	$ 1,316,503	$ 4,083,300	$ 16,249
Conversion price per share					$ 0.75
Convertible promissory note, principal amount			$ 5,000,000	$ 5,000,000
Convertible promissory note shares issued upon conversion				6,666,667

Stockholders' Equity (Stockholder Rights Plan) - Additional Information (Detail) (Stockholder Rights Plan [Member], USD $)	0 Months Ended
	Sep. 20, 2011	Sep. 20, 2011
Stockholder Rights Plan [Member]
Stockholders' Equity [Line Items]
Warrants exercise price		$ 7.80
Minimum percentage of outstanding stock acquired by a person or group to trigger Shareholder Rights Plan	17.50%
Stockholders Rights Plan redemption price of right		$ 0.001
Class of warrant or right expiration date	Sep. 20, 2016

Stock Compensation (Summary) - Additional Information (Detail)	12 Months Ended
	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options granted pursuant to written agreements to date	1,305,000
2006 Stock Incentive Plan [Member] \| Common Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options granted pursuant to written agreements to date	2,352,254
Common stock shares available for future issuance under the Plan	0
2014 Stock Incentive Plan [Member] \| Common Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock shares available for future issuance under the Plan	2,640,000
Common stock shares reserved for issuance under the Plan	4,000,000

Stock Compensation (Stock Options) - Additional Information (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option contractual term	1 year 10 months 28 days
Number of stock options exercised	765,000
Proceeds from exercise of options	$ 522,000	$ 23,500
Stock options granted	1,305,000
Expected dividend rate	0.00%	0.00%	0.00%
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of stock options exercised	580,000	50,000
Proceeds from exercise of options	522,000	23,500
Number of stock options exercised cashless	185,000
Shares issued for cashless option exercise	119,709
Non-cash stock-based compensation expense	767,838	175,855	340,039
Stock option granted, contractual term		5 years	5 years
Stock options granted	1,305,000	115,000	975,000
Unrecognized compensation expense related to non-vested stock option awards granted under the Plan	$ 2,400,000
Expected remaining weighted average vesting period	2 years 6 months
Expected dividend rate	0.00%
Stock Options [Member] \| Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option vesting period	2 years
Stock option contractual term	5 years
Stock option granted, contractual term	5 years
Stock Options [Member] \| Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option vesting period	4 years
Stock option contractual term	10 years
Stock option granted, contractual term	7 years

Stock Compensation Plans - Summary of Stock Option Activity under the Company's Written Stock Option Agreements and the Plan (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Number of options, Outstanding at beginning of year	3,428,906
Number of options, Granted	1,305,000
Number of options, Exercised	(765,000)
Number of options, Forfeited or cancelled	(50,000)
Number of options, Expired	(34,296)
Number of options, Outstanding at end of year	3,884,610
Number of options, Exercisable at end of year	2,687,943
Weighted average exercise price, Outstanding at beginning of year	$ 0.80
Weighted average exercise price, Granted	$ 3.08
Weighted average exercise price, Exercised	$ 0.90
Weighted average exercise price, Forfeited or cancelled	$ 2.71
Weighted average exercise price, Expired	$ 3.28
Weighted average exercise price, Outstanding at end of year	$ 1.50
Weighted average exercise price, Exercisable at end of year	$ 0.86
Weighted Average Remaining Contractual Term (Years), Outstanding at end of year	3 years 3 months 15 days
Weighted Average Remaining Contractual Term (Years), Exercisable at end of year	1 year 10 months 28 days
Aggregate Intrinsic value, Outstanding at end of year	$ 5,897,040
Aggregate Intrinsic value, Exercisable at end of year	$ 5,703,106

Stock Compensation Plans - Schedule of Other Information Pertaining to Stock Option Activity (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Weighted average fair value of granted stock options	$ 2.41	$ 0.48	$ 0.32
Total fair value of vested stock options	$ 409,476	$ 166,633	$ 348,815
Total intrinsic value of exercised stock options	$ 1,339,100	$ 17,975	$ 40,050

Stock Compensation Plan - Summary of Company's Stock Options Outstanding (Detail) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Exercise Prices Lower Range	$ 0.47	$ 0.47	$ 0.47
Range of Exercise Prices Upper Range	$ 3.12	$ 6.00	$ 6.00
Number Outstanding, Options Outstanding	3,884,610
Weighted Average Remaining Contractual Life (Years), Options Outstanding	3 years 3 months 15 days
Weighted Average Exercise Price, Options Outstanding	$ 1.50
Number Exercisable Options Exercisable	2,687,943
Weighted Average Remaining Contractual Life (Years), Options Exercisable	1 year 10 months 28 days
Weighted Average Exercise Price, Options Exercisable	$ 0.86
$0.47 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Exercise Prices	$ 0.47
Number Outstanding, Options Outstanding	1,000,000
Weighted Average Remaining Contractual Life (Years), Options Outstanding	2 years 11 months 19 days
Weighted Average Exercise Price, Options Outstanding	$ 0.47
Number Exercisable Options Exercisable	950,000
Weighted Average Remaining Contractual Life (Years), Options Exercisable	2 years 11 months 12 days
Weighted Average Exercise Price, Options Exercisable	$ 0.47
$0.69 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Exercise Prices	$ 0.69
Number Outstanding, Options Outstanding	729,610
Weighted Average Remaining Contractual Life (Years), Options Outstanding	2 months 1 day
Weighted Average Exercise Price, Options Outstanding	$ 0.69
Number Exercisable Options Exercisable	729,610
Weighted Average Remaining Contractual Life (Years), Options Exercisable	2 months 1 day
Weighted Average Exercise Price, Options Exercisable	$ 0.69
$0.85 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Exercise Prices	$ 0.85
Number Outstanding, Options Outstanding	40,000
Weighted Average Remaining Contractual Life (Years), Options Outstanding	3 years 4 months 21 days
Weighted Average Exercise Price, Options Outstanding	$ 0.85
Number Exercisable Options Exercisable	13,333
Weighted Average Remaining Contractual Life (Years), Options Exercisable	3 years 4 months 21 days
Weighted Average Exercise Price, Options Exercisable	$ 0.85
$1.07 - $1.09 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Exercise Prices Lower Range	$ 1.07
Range of Exercise Prices Upper Range	$ 1.09
Number Outstanding, Options Outstanding	860,000
Weighted Average Remaining Contractual Life (Years), Options Outstanding	1 year 5 months 23 days
Weighted Average Exercise Price, Options Outstanding	$ 1.08
Number Exercisable Options Exercisable	860,000
Weighted Average Remaining Contractual Life (Years), Options Exercisable	1 year 5 months 23 days
Weighted Average Exercise Price, Options Exercisable	$ 1.08
$2.34 - 2.35 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Exercise Prices Lower Range	$ 2.34
Range of Exercise Prices Upper Range	$ 2.35
Number Outstanding, Options Outstanding	30,000
Weighted Average Remaining Contractual Life (Years), Options Outstanding	4 years 4 months 21 days
Weighted Average Exercise Price, Options Outstanding	$ 2.35
Number Exercisable Options Exercisable	10,000
Weighted Average Remaining Contractual Life (Years), Options Exercisable	4 years 2 months 27 days
Weighted Average Exercise Price, Options Exercisable	$ 2.34
$3.03 - 3.12 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Range of Exercise Prices Lower Range	$ 3.03
Range of Exercise Prices Upper Range	$ 3.12
Number Outstanding, Options Outstanding	1,225,000
Weighted Average Remaining Contractual Life (Years), Options Outstanding	6 years 8 months 1 day
Weighted Average Exercise Price, Options Outstanding	$ 3.12
Number Exercisable Options Exercisable	125,000
Weighted Average Remaining Contractual Life (Years), Options Exercisable	6 years 7 months 28 days
Weighted Average Exercise Price, Options Exercisable	$ 3.12

Stock Compensation Plans - Summary of Stock Options Awards Based on Certain Assumptions (Detail)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate, Minimum	1.18%	0.45%	0.28%
Risk free interest rate, Maximum	2.03%	0.53%	0.66%
Expected term		3 years
Expected volatility	115.00%	137.00%	120.00%
Expected dividend yield	0.00%	0.00%	0.00%
Expected forfeiture rate	0.00%	0.00%	0.00%
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term	3 years		3 years
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected term	7 years		5 years

Stock Compensation (Restricted Stock Units) - Additional Information (Detail) (Restricted Stock Units (RSUs) [Member], USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Non-cash stock-based compensation expense	$ 10,131	$ 0	$ 0
Minimum [Member] \| Two Thousand Fourteen Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option vesting period	3 years
Maximum [Member] \| Two Thousand Fourteen Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock option vesting period	4 years

Stock Compensation Plans - Summary of Restricted Stock Unit Activity (Detail) (Restricted Stock Units (RSUs) [Member], USD $)	12 Months Ended
	Dec. 31, 2014
Restricted Stock Units (RSUs) [Member]
Schedule Of Restricted Stock Activity [Line Items]
Nonvested balance at beginning of year	0
Granted	80,000
Vested	0
Forfeited	0
Nonvested balance at end of year	80,000
Nonvested Weighted Average Grant Date Fair Value balance at beginning of year	$ 0
Weighted Average Grant Date Fair Value, Granted	$ 2.83
Weighted Average Grant Date Fair Value, Vested	$ 0
Weighted Average Grant Date Fair Value, Forfeited	$ 0
Nonvested Weighted Average Grant Date Fair Value balance at end of year	$ 2.83

Benefit Plan - Additional Information (Detail) (USD $)	12 Months Ended
Benefit Plan - Additional Information (Detail) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Compensation and Retirement Disclosure [Abstract]
Employees contribution of pre-tax annual compensation	15.00%
Discretionary matching contributions of employee contributions of an employee's gross salary	4.00%
Contributions	$ 44,000	$ 30,000	$ 28,000

Quarterly Financial Information (Unaudited) - Schedule of Quarterly Financial Information (Detail) (USD $)	3 Months Ended								12 Months Ended
	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Quarterly Financial Information Disclosure [Abstract]
Revenues	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0	$ 0
Loss from operations	(3,983,861)	(4,109,029)	(2,990,173)	(3,508,365)	(2,706,923)	(3,245,776)	(2,653,529)	(1,705,430)	(14,591,428)	(10,311,658)	(5,221,140)
Change in fair value of warrants liability	472,026	(906,787)	(223,591)	(335,514)	1,330,155	(2,676,601)	(498,587)	(45,326)	993,866	1,890,359	(1,129,778)
Net loss	$ (3,490,030)	$ (5,009,892)	$ (3,198,020)	$ (3,811,119)	$ (1,354,658)	$ (5,912,059)	$ (3,143,590)	$ (1,744,289)	$ (15,509,061)	$ (12,154,596)	$ (4,076,386)
Loss per share-basic and diluted	$ (0.05)	$ (0.07)	$ (0.05)	$ (0.07)	$ (0.03)	$ (0.13)	$ (0.08)	$ (0.04)	$ (0.24)	$ (0.27)	$ (0.14)

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References+ Details

Subsequent Event - Additional Information (Detail) (USD $)	12 Months Ended			0 Months Ended		0 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Apr. 03, 2014 2014 Shelf Registration Statement [Member] Underwritten Public Offering [Member]	Apr. 03, 2014 2014 Shelf Registration Statement [Member] Underwritten Public Offering [Member]	Mar. 03, 2015 Subsequent Event [Member]	Mar. 03, 2015 Subsequent Event [Member] Warrant [Member]	Feb. 04, 2015 Subsequent Event [Member] 2014 Shelf Registration Statement [Member] Underwritten Public Offering [Member]	Feb. 04, 2015 Subsequent Event [Member] 2014 Shelf Registration Statement [Member] Underwritten Public Offering [Member]
Subsequent Event [Line Items]
Number of common stock shares issued				13,023,750			152,174	11,500,000
Common stock issued, price per share					$ 2.21				$ 3.25
Gross proceeds from issuance of common stock				$ 28,800,000				$ 37,400,000
Offering expenses				2,100,000				2,700,000
Proceeds from exercise of warrants	$ 1,316,503	$ 4,083,300	$ 16,249			$ 198,000
Number of stock options exercised	765,000					829,608
Shares issued for cashless option exercise						673,583

- Definition

Number of share options (or share units) exercised during the current period.

+ References+ Details

Agreements (BROOKHAVEN) - Additional Information (Detail) (License Agreement with Brookhaven [Member], USD $)	12 Months Ended
	Dec. 31, 2014
License Agreement with Brookhaven [Member]
License Agreement [Line Items]
Expiry date of licensed patents	2023
License fee paid	$ 50,000